Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin
Identifieur interne : 009520 ( Main/Exploration ); précédent : 009519; suivant : 009521Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin
Auteurs : Philip J. Cooper ; Lawrence B. Schwartz ; Anne-Marie Irani ; Kwablah Awadzi [Ghana] ; Ronald H. Guderian [Équateur] ; Thomas B. NutmanSource :
- The Journal of Infectious Diseases [ 0022-1899 ] ; 2002-11-01.
Descripteurs français
- KwdFr :
- Animaux, Antihelminthiques (effets indésirables), Humains, Interleukine-5 (sang), Ivermectine (effets indésirables), Lymphoedème (), Marqueurs biologiques (sang), Mastocytes (parasitologie), Mastocytes (physiologie), Mastocytose cutanée (), Onchocerca (pathogénicité), Onchocercose (traitement médicamenteux), Serine endopeptidases (sang), Tryptases, Éosinophilie ().
- MESH :
- effets indésirables : Antihelminthiques, Ivermectine.
- parasitologie : Mastocytes.
- pathogénicité : Onchocerca.
- physiologie : Mastocytes.
- sang : Interleukine-5, Marqueurs biologiques, Serine endopeptidases.
- traitement médicamenteux : Onchocercose.
- Animaux, Humains, Lymphoedème, Mastocytose cutanée, Tryptases, Éosinophilie.
English descriptors
- KwdEn :
- Animals, Anthelmintics (adverse effects), Biomarkers (blood), Eosinophilia (chemically induced), Humans, Interleukin-5 (blood), Ivermectin (adverse effects), Lymphedema (chemically induced), Mast Cells (parasitology), Mast Cells (physiology), Mastocytosis, Cutaneous (chemically induced), Onchocerca (pathogenicity), Onchocerciasis (drug therapy), Serine Endopeptidases (blood), Tryptases.
- MESH :
- chemical , adverse effects : Anthelmintics, Ivermectin.
- chemical , blood : Biomarkers, Interleukin-5, Serine Endopeptidases.
- chemically induced : Eosinophilia, Lymphedema, Mastocytosis, Cutaneous.
- drug therapy : Onchocerciasis.
- parasitology : Mast Cells.
- pathogenicity : Onchocerca.
- physiology : Mast Cells.
- Animals, Humans, Tryptases.
Abstract
To investigate the role of mast cells in treatment-associated adverse reactions in patients with onchocerciasis, changes in plasma tryptase levels and skin mast cell counts were examined in 2 groups of Onchocerca volvulus–infected subjects after ivermectin treatment. After treatment, an increase in tryptase levels was observed concurrent with the onset of blood eosinopenia and preceding the appearance of plasma eosinophil-derived neurotoxin (EDN) and interleukin-5. Tryptase levels were correlated with development of peripheral eosinopenia and markers of eosinophil activation and degranulation. Dermal mast cell numbers increased transiently at 24 h after treatment, preceding the onset of dermal eosinophil infiltration and the development of clinically apparent inflammation. Local reactions were strongly correlated with levels of plasma tryptase and EDN, and the severity of systemic reactions was correlated with levels of tryptase, EDN, and interleukin-5. The data indicate that mast cells play a role in initiation of tissue inflammatory reactions after ivermectin treatment of onchocerciasis
Url:
DOI: 10.1086/344318
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001982
- to stream Istex, to step Curation: 001982
- to stream Istex, to step Checkpoint: 002463
- to stream PubMed, to step Corpus: 004444
- to stream PubMed, to step Curation: 004444
- to stream PubMed, to step Checkpoint: 004444
- to stream Ncbi, to step Merge: 000B46
- to stream Ncbi, to step Curation: 000B46
- to stream Ncbi, to step Checkpoint: 000B46
- to stream Main, to step Merge: 009901
- to stream Main, to step Curation: 009520
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin</title><author><name sortKey="Cooper, Philip J" sort="Cooper, Philip J" uniqKey="Cooper P" first="Philip J." last="Cooper">Philip J. Cooper</name></author><author><name sortKey="Schwartz, Lawrence B" sort="Schwartz, Lawrence B" uniqKey="Schwartz L" first="Lawrence B." last="Schwartz">Lawrence B. Schwartz</name></author><author><name sortKey="Irani, Anne Marie" sort="Irani, Anne Marie" uniqKey="Irani A" first="Anne-Marie" last="Irani">Anne-Marie Irani</name></author><author><name sortKey="Awadzi, Kwablah" sort="Awadzi, Kwablah" uniqKey="Awadzi K" first="Kwablah" last="Awadzi">Kwablah Awadzi</name></author><author><name sortKey="Guderian, Ronald H" sort="Guderian, Ronald H" uniqKey="Guderian R" first="Ronald H." last="Guderian">Ronald H. Guderian</name></author><author><name sortKey="Nutman, Thomas B" sort="Nutman, Thomas B" uniqKey="Nutman T" first="Thomas B." last="Nutman">Thomas B. Nutman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:37DF7574C3F2357A984CDEAAE6FF181CE100C014</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1086/344318</idno><idno type="url">https://api.istex.fr/document/37DF7574C3F2357A984CDEAAE6FF181CE100C014/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001982</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001982</idno><idno type="wicri:Area/Istex/Curation">001982</idno><idno type="wicri:Area/Istex/Checkpoint">002463</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002463</idno><idno type="wicri:doubleKey">0022-1899:2002:Cooper P:association:of:transient</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12402200</idno><idno type="wicri:Area/PubMed/Corpus">004444</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004444</idno><idno type="wicri:Area/PubMed/Curation">004444</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004444</idno><idno type="wicri:Area/PubMed/Checkpoint">004444</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004444</idno><idno type="wicri:Area/Ncbi/Merge">000B46</idno><idno type="wicri:Area/Ncbi/Curation">000B46</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B46</idno><idno type="wicri:doubleKey">0022-1899:2002:Cooper P:association:of:transient</idno><idno type="wicri:Area/Main/Merge">009901</idno><idno type="wicri:Area/Main/Curation">009520</idno><idno type="wicri:Area/Main/Exploration">009520</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin</title><author><name sortKey="Cooper, Philip J" sort="Cooper, Philip J" uniqKey="Cooper P" first="Philip J." last="Cooper">Philip J. Cooper</name><affiliation></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: pc102d@hotmail.com</wicri:noCountry></affiliation></author><author><name sortKey="Schwartz, Lawrence B" sort="Schwartz, Lawrence B" uniqKey="Schwartz L" first="Lawrence B." last="Schwartz">Lawrence B. Schwartz</name><affiliation><wicri:noCountry code="subField">Richmond;</wicri:noCountry></affiliation></author><author><name sortKey="Irani, Anne Marie" sort="Irani, Anne Marie" uniqKey="Irani A" first="Anne-Marie" last="Irani">Anne-Marie Irani</name><affiliation><wicri:noCountry code="subField">Richmond;</wicri:noCountry></affiliation></author><author><name sortKey="Awadzi, Kwablah" sort="Awadzi, Kwablah" uniqKey="Awadzi K" first="Kwablah" last="Awadzi">Kwablah Awadzi</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Ghana</country><wicri:regionArea>Onchocerciasis Chemotherapy Research Centre, Hohoe Hospital, Hohoe</wicri:regionArea><wicri:noRegion>Hohoe</wicri:noRegion></affiliation></author><author><name sortKey="Guderian, Ronald H" sort="Guderian, Ronald H" uniqKey="Guderian R" first="Ronald H." last="Guderian">Ronald H. Guderian</name><affiliation wicri:level="1"><country xml:lang="fr">Équateur</country><wicri:regionArea>Department of Clinical Investigations, Hospital Vozandes, Quito</wicri:regionArea><wicri:noRegion>Quito</wicri:noRegion></affiliation></author><author><name sortKey="Nutman, Thomas B" sort="Nutman, Thomas B" uniqKey="Nutman T" first="Thomas B." last="Nutman">Thomas B. Nutman</name><affiliation><wicri:noCountry code="subField">Maryland;</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="2002-11-01">2002-11-01</date><biblScope unit="volume">186</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1307">1307</biblScope><biblScope unit="page" to="1313">1313</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anthelmintics (adverse effects)</term><term>Biomarkers (blood)</term><term>Eosinophilia (chemically induced)</term><term>Humans</term><term>Interleukin-5 (blood)</term><term>Ivermectin (adverse effects)</term><term>Lymphedema (chemically induced)</term><term>Mast Cells (parasitology)</term><term>Mast Cells (physiology)</term><term>Mastocytosis, Cutaneous (chemically induced)</term><term>Onchocerca (pathogenicity)</term><term>Onchocerciasis (drug therapy)</term><term>Serine Endopeptidases (blood)</term><term>Tryptases</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antihelminthiques (effets indésirables)</term><term>Humains</term><term>Interleukine-5 (sang)</term><term>Ivermectine (effets indésirables)</term><term>Lymphoedème ()</term><term>Marqueurs biologiques (sang)</term><term>Mastocytes (parasitologie)</term><term>Mastocytes (physiologie)</term><term>Mastocytose cutanée ()</term><term>Onchocerca (pathogénicité)</term><term>Onchocercose (traitement médicamenteux)</term><term>Serine endopeptidases (sang)</term><term>Tryptases</term><term>Éosinophilie ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Interleukin-5</term><term>Serine Endopeptidases</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Eosinophilia</term><term>Lymphedema</term><term>Mastocytosis, Cutaneous</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antihelminthiques</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Mastocytes</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Mast Cells</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Onchocerca</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Onchocerca</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Mastocytes</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Mast Cells</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Interleukine-5</term><term>Marqueurs biologiques</term><term>Serine endopeptidases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Onchocercose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Tryptases</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Lymphoedème</term><term>Mastocytose cutanée</term><term>Tryptases</term><term>Éosinophilie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">To investigate the role of mast cells in treatment-associated adverse reactions in patients with onchocerciasis, changes in plasma tryptase levels and skin mast cell counts were examined in 2 groups of Onchocerca volvulus–infected subjects after ivermectin treatment. After treatment, an increase in tryptase levels was observed concurrent with the onset of blood eosinopenia and preceding the appearance of plasma eosinophil-derived neurotoxin (EDN) and interleukin-5. Tryptase levels were correlated with development of peripheral eosinopenia and markers of eosinophil activation and degranulation. Dermal mast cell numbers increased transiently at 24 h after treatment, preceding the onset of dermal eosinophil infiltration and the development of clinically apparent inflammation. Local reactions were strongly correlated with levels of plasma tryptase and EDN, and the severity of systemic reactions was correlated with levels of tryptase, EDN, and interleukin-5. The data indicate that mast cells play a role in initiation of tissue inflammatory reactions after ivermectin treatment of onchocerciasis</div></front></TEI><affiliations><list><country><li>Ghana</li><li>Équateur</li></country></list><tree><noCountry><name sortKey="Cooper, Philip J" sort="Cooper, Philip J" uniqKey="Cooper P" first="Philip J." last="Cooper">Philip J. Cooper</name><name sortKey="Irani, Anne Marie" sort="Irani, Anne Marie" uniqKey="Irani A" first="Anne-Marie" last="Irani">Anne-Marie Irani</name><name sortKey="Nutman, Thomas B" sort="Nutman, Thomas B" uniqKey="Nutman T" first="Thomas B." last="Nutman">Thomas B. Nutman</name><name sortKey="Schwartz, Lawrence B" sort="Schwartz, Lawrence B" uniqKey="Schwartz L" first="Lawrence B." last="Schwartz">Lawrence B. Schwartz</name></noCountry><country name="Ghana"><noRegion><name sortKey="Awadzi, Kwablah" sort="Awadzi, Kwablah" uniqKey="Awadzi K" first="Kwablah" last="Awadzi">Kwablah Awadzi</name></noRegion></country><country name="Équateur"><noRegion><name sortKey="Guderian, Ronald H" sort="Guderian, Ronald H" uniqKey="Guderian R" first="Ronald H." last="Guderian">Ronald H. Guderian</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:37DF7574C3F2357A984CDEAAE6FF181CE100C014
|texte= Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin
}}
| This area was generated with Dilib version V0.6.31. |  |